Effect of peritoneal dialysis in end-stage renal disease on apixaban pharmacokinetics

Nephrol Dial Transplant. 2023 Jul 31;38(8):1918-1920. doi: 10.1093/ndt/gfad087.

Laure Peyro-Saint-Paul¹, Clémence Bechade^{2

3}, Alexandre Cesbron⁴, Danièle Debruyne⁴, Marie Brionne⁵, Sylvie Brucato⁶, Mélanie Hanoy⁷, Audrey Dumont^{8

9}, Anais R Briant¹⁰, Jean-Jacques Parienti^{10

11}, Thierry Lobbedez^{2

3}, Maxence Ficheux¹²

¹ CHU de Caen Normandie, Department of Clinical Research and Biostatistics, Caen, France.
² Department of Nephrology, Normandie University, UNICAEN, CHU de Caen Normandie, Caen, France.
³ ANTICIPE, U1086 INSERM-UCN, Centre François Baclesse, Caen, France.
⁴ CHU de Caen Normandie, Pharmacologie, Caen, France.
⁵ CHU de Caen Normandie, Hématologie Biologique, Caen, France.
⁶ CHU de Caen Normandie, Centre de Recherche Clinique, Caen, France.
⁷ CHU Rouen, Nephrology, Dialysis and Kidney Transplantation, Rouen, France.
⁸ Univ Rouen Normandie, INSERM EnVI U1096, "Endothelium, Valvulopathy and Heart Failure".
⁹ CHU Rouen, CIC-CRB 1404, Department of Pharmacology, Rouen, France.
¹⁰ Department of Clinical Research and Biostatistics, CHU de Caen Normandie and Caen Normandy University, Caen, France.
¹¹ INSERM U1311 DYNAMICURE, Caen Normandy University, Caen, France.
¹² CHU de Caen Normandie, Néphrologie, Caen, France.

No abstract available

Publication types